December 12, 2017 9:33 AM ET


Company Overview of Boston Therapeutics, Inc.

Company Overview

Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements to address blood sugar management and inflammatory diseases in the United States. Its lead pharmaceutical drug candidates include BTI-320, a non-systemic, carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic patients, pre diabetic patients; and IPOXYN, a carbohydrate-based, injectable drug, which is in pre-clinical stage to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such ...

354 Merrimack Street

Suite 4

Lawrence, MA 01843

United States

Founded in 2009



Key Executives for Boston Therapeutics, Inc.

CEO, CFO & Director
Age: 68
Total Annual Compensation: $153.9K
Compensation as of Fiscal Year 2016.

Boston Therapeutics, Inc. Key Developments

Boston Therapeutics, Inc. Announces New Dosing Regimen for BTI320

Boston Therapeutics, Inc. announced that effective sugar reduction with the investigative BTI320 formulation requires only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN®, SUGARBLOCK and SUGARBALANCE in USA and Asia. Results of this study ( were presented at the 77th American Diabetes Association (ADA) conference in June 2017 and exhibited that one tablet was effective in lowering the one and two-hour postprandial glucose levels in pre-diabetic subjects. The investigative BTI320 formulation has been shown to lower postprandial glucose excursions and significantly reduce glycemic variability in high-risk individuals with pre-diabetes. In China alone, 110 million people were suffering from type 2 diabetes in 2015. This number is expected to grow to 151 million by 2040. The impact of treating people sooner than later cannot be understated and non-systemic option like BTI320 may have an important impact on the progression of disease.

Rom Eliaz Resigns as Director of Boston Therapeutics, Inc

On June 16, 2017, Rom Eliaz resigned as a director of Boston Therapeutics, Inc.

Boston Therapeutics, Inc. Appoints Carl W. Rausch as Director

On November 23, 2016, Carl W. Rausch was appointed by Boston Therapeutics, Inc. to serve as a director of the Company. Mr. Rausch is the Chief Executive Officer of the Company. From 2006 to 2008, Mr. Rausch was a principal with Biotechnology Partners, which provided advisory services to biotechnology clients. Mr. Rausch served as the Vice Chairman and Chief Technical Officer of Biopure Corporation from 2002 to 2005. Mr. Rausch cofounded Biopure in 1984. From 1984 until 2002, Mr. Rausch served as Chairman and Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Private Placement
August 14, 2017
Private Placement
April 26, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Boston Therapeutics, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at